

UC Merced

UC Merced Previously Published Works

Title

Assessing Protein Sequence Database Suitability Using De Novo Sequencing*

Permalink

<https://escholarship.org/uc/item/9x95k94f>

Journal

Molecular & Cellular Proteomics, 19(1)

ISSN

1535-9476

Authors

Johnson, Richard S
Searle, Brian C
Nunn, Brook L
et al.

Publication Date

2020

DOI

10.1074/mcp.tir119.001752

Peer reviewed

Assessing Protein Sequence Database Suitability Using *De Novo* Sequencing

Authors

Richard S. Johnson, Brian C. Searle, Brook L. Nunn, Jason M. Gilmore, Molly Phillips, Chris T. Amemiya, Michelle Heck, and Michael J. MacCoss

Correspondence

rj8@uw.edu

In Brief

The success of a sample preparation method can be difficult to evaluate for unusual or unfamiliar samples. Further, it can be hard to discern the suitability of a chosen database for a search of such data. Automated *de novo* sequencing can provide metrics for both problems.

Graphical Abstract

	FASTA	<i>de novo</i>
Scan 1	SAAAGVNPIVER	ASQVGGPLDLR
Scan 2	KHPDSSVNFAEFSK	HKPMWANFAEFSK
Scan 3	AIQDHLLVEQSKDQMEK	ALQDHLADEEVELLASMEK
Scan 4	MNDLTIIQTTQGFCR	AAFDKDGNGYLSAAELR
...

$$\text{Database Suitability Metric} = \frac{\text{Database scores better}}{\text{Database or } de\ novo}$$

Highlights

- An automated *de novo* sequencing program is evaluated with respect to different types of data.
- The number of unique high scoring *de novo* sequences that can be assigned to a data set provides a metric of overall data quality.
- A database suitability metric is presented for situations when the database choice is not obvious, or when the database quality is uncertain.

Assessing Protein Sequence Database Suitability Using *De Novo* Sequencing*[§]

Richard S. Johnson[‡], Brian C. Searle[¶], Brook L. Nunn[‡], Jason M. Gilmore[‡], Molly Phillips[¶], Chris T. Amemiya^{||}, Michelle Heck^{**}, and Michael J. MacCoss[‡]

The analysis of samples from unsequenced and/or understudied species as well as samples where the proteome is derived from multiple organisms poses two key questions. The first is whether the proteomic data obtained from an unusual sample type even contains peptide tandem mass spectra. The second question is whether an appropriate protein sequence database is available for proteomic searches. We describe the use of automated *de novo* sequencing for evaluating both the quality of a collection of tandem mass spectra and the suitability of a given protein sequence database for searching that data. Applications of this method include the proteome analysis of closely related species, metaproteomics, and proteomics of extinct organisms. *Molecular & Cellular Proteomics* 19: 198–208, 2020. DOI: 10.1074/mcp.TIR119.001752.

Matching tandem mass spectra to database-derived sequences is routine, and a variety of software pipelines are available (1). However, atypical and new types of samples can be problematic. For example, it can be difficult to evaluate sample preparation methods using LCMS/MS data from fossils, soil, or glacial meltwaters, when such samples are new to the research community, DNA is unattainable, or there is no obvious protein database to search. If the genome of the organism under study is unknown, or if the sample comes from multiple unknown species (*i.e.* metaproteomics) the suitability of a chosen sequence database can be difficult to evaluate (2). In the case of species whose genomes are unsequenced, data analysis typically employs a protein sequence database from a taxonomically related species, where the hope is that the sequences are mostly identical (3). For metaproteomics, the standard approach is to sequence the DNA in the sample, assemble a metagenome, and translate it into protein sequences as a FASTA formatted file (4). The hope is that there are no mistakes in assembly and translation to protein sequence, and that the translated metagenome accurately represents the metaproteome under study. Once a FASTA file is created, a database search is performed and the

number of identifications is reported, yet it is not clear how many high-quality tandem mass spectra failed to make a match because the peptide sequence was not represented in the FASTA file. If there is more than one sequence database to choose from (*e.g.* because of different gene assembly methods), the one with the largest number of identifications over a range of false discovery rates is the optimal choice. Although this is a valid way to proceed, one cannot know if a low number of identifications is because of bad tandem mass spectrometry (MS/MS)¹ data, an inappropriate or insufficient sequence database, or both. Here we propose and evaluate a simple solution that uses automated *de novo* sequencing to evaluate both tandem mass spectrum quality and sequence database suitability.

De novo sequencing is the concept of deriving a peptide sequence from a tandem mass spectrum without use of a sequence database (5). Before the existence of sequence databases (or ready access to powerful computers), *de novo* sequencing was the only approach to interpret tandem mass spectra of peptides. The degree to which one can successfully derive a sequence is dependent on spectral quality. Specifically, spectra that can be sequenced possess a contiguous series of sequencing ions of the same type (*e.g.* b- and y-type ions), which turns out to be the case for low energy collision induced dissociation (CID) of tryptic peptides. In the past, automated *de novo* sequencing has had difficulty deriving accurate sequences in a timely manner; however, the accuracy of the sequences and associated scores improved markedly with the use of high mass accuracy analyzers such as time-of-flight or orbitrap instruments. The recently developed automated *de novo* sequencing program called Novor (6) has eliminated the speed limitation in that the software can generate *de novo* sequences faster than it takes to acquire the data (and generally in less time than a database search of the same data). The question now is: what should we do with these *de novo* interpretations?

Here we describe an approach that utilizes Novor to assess tandem mass spectra quality and the suitability of FASTA files

From the Departments of [‡]Genome Sciences and [¶]Biology, University of Washington, Seattle, Washington; [§]Institute for Systems Biology, Seattle, Washington; [¶]Proteome Software, Portland, Oregon; ^{||}School of Natural Sciences, University of California, Merced, California; ^{**}United States Department of Agriculture, Agricultural Research Service, Ithaca, New York

Received August 22, 2019, and in revised form, October 31, 2019

Published, MCP Papers in Press, November 15, 2019, DOI 10.1074/mcp.TIR119.001752

for database searches. Finding many high scoring *de novo* sequences in a data set implies that many high-quality tandem mass spectra of peptides are present (7). Likewise, comparison of *de novo* sequencing results with database search results (all from the same data file and scored with the same database search algorithm) can be used to determine the suitability of a chosen FASTA file. The strategy is to append *de novo* sequences to the FASTA file under study, run a standard database search of the modified FASTA file, and compare the ranking of the *de novo* sequences with the original FASTA file sequences. Returning a higher number of matches to the original FASTA file sequences, compared with the *de novo* sequences, implies that the FASTA file is suitable for use in a database search. Here we show that automated *de novo* sequencing using Novor provides a simple and fast means of evaluating both tandem mass spectra and FASTA file quality.

EXPERIMENTAL PROCEDURES

Sample Preparation—A human K562 cell extract was obtained from Promega (Madison, WI). A *C. elegans* tryptic digest was prepared as previously described (8). Tryptic digests of whole Asian citrus psyllids (*D. citri*) were performed as described (9). One hundred milligrams of powdered cave bear bone provided by Richard E. Green (University of California, Santa Cruz, CA) (10–12) was placed in 500 μ l of 0.2% PPS Silent Surfactant (Expedeon San Diego, CA) in 50 mM ammonium bicarbonate (ABC), and probe sonicated three times for 20 s while on ice. An additional 500 μ l of 50 mM ABC brought the final extract to 1.0 ml in 0.1% PPS. The extract was centrifuged, and the supernatant shown to contain 1.2 mg/ml total protein using a BCA assay. A spotted ratfish (*Hydrolagus colliei*) and a little skate (*Leucoraja erinacea*) were collected and euthanized in compliance with IACUC protocol numbers, IACUC16–014 and AUP18–0001 respectively. The ratfish was collected from Puget Sound and experimentation was carried out at the Benaroya Research Institute in Seattle, WA. The skate was shipped from the Marine Biological Laboratory in Woods Hole, MA to the University of California, Merced where studies were performed. For both specimens, viscous hydrogel found within the electrosensory ampullae of Lorenzini was extracted by applying pressure on the organs externally. Dilution of 100 μ l of this material with 200 μ l of 0.2% PPS and 50 mM Tris buffer at pH 8 reduced the sample viscosity before tryptic digestion. Glacial silt from Greenland meltwater was isolated at the field site. Sample preparation, including DNA extraction, is described in detail in the supplemental section.

Reduction and alkylation of disulfide bonds employed treatment with 5 mM tris(2-carboxyethyl) phosphine for an hour at 37 C, cooling to room temperature, and adding 5.5 mM iodoacetamide at room temperature for 20 min. Tryptic digestion proceeded overnight using 1:50 by weight of Promega trypsin at 37 C. Digestion was stopped and PPS cleaved by acidification with trifluoroacetic acid (TFA) (0.2% by volume and pH 2, as verified by pH paper). In most cases, the tryptic digestions were analyzed directly; however, the fish hydrogel samples were subjected to solid phase extraction using MCX car-

tridges (Waters) per manufacturer's instructions, dried on a vacuum centrifuge, and resolubilized in 100 μ l of 2% acetonitrile containing 0.1% TFA.

Data Acquisition—All mass spectrometry was performed on either a Fusion Orbitrap or Q-Exactive-HF (Thermo Fisher Scientific, San Jose, CA) mass spectrometer. Up to 1 μ g of each sample digest was loaded from the autosampler onto a 150- μ m inner diameter (ID) Kasil fritted trap packed with Reprosil-Pur C18-AQ (3- μ m bead diameter, Dr. Maisch Ammerbuch, Germany) to a bed length of 2 cm at a flow rate of 2 μ l/min. After loading and desalting using a total volume of 10 μ l of 0.1% formic acid plus 2% acetonitrile, the trap was brought on-line with a pulled fused-silica capillary tip (75- μ m ID) packed with the same Reprosil C18-AQ that was mounted in a microspray source and placed in line with a Waters Nanoacquity binary UPLC pump plus autosampler. Peptides were eluted off the column using a gradient of 2–35% acetonitrile in 0.1% formic acid over 60 min, followed by 35–60% acetonitrile over 5 min at a flow rate of 250 nl/min. The mass spectrometers were operated using electrospray ionization (2 kV) with the heated transfer tube at 275 C using data dependent acquisition (DDA) in the so-called "Top Speed" mode (Fusion), or "Top 20" mode (Q-Exactive). The orbitrap resolution was 120,000 at *m/z* 200, and for tandem mass spectrometry (MS/MS) the linear ion trap provided unit resolution or the orbitrap was operated at a resolving power of 15,000. Unless otherwise specified, the MS/MS spectra were acquired using a quadrupole isolation width of 1.6 *m/z* and HCD normalized collision energy (NCE) of 30%, or CID collision energy of 35%. Dynamic exclusion (including all isotope peaks) was set for 30 s using monoisotopic precursor selection. Data file format conversions were made with Proteowizard version 3.0.19053 (13).

Novor—*De novo* sequences were generated using the program Novor (v1.5.573) (6), and unless otherwise specified the following parameters were used - Enzyme: Trypsin, Instrument Type: HCD-FT, Precursor Error Tolerance: 10 ppm, Fragment Error Tolerance: 0.02 Da, and no variable modifications were considered, but the appropriate cysteine modification was used as a fixed modification. Novor produces a csv output file that includes the *de novo* sequence and a sequence score.

Evaluation of the Novor scores was performed by comparing high confidence peptide sequence search results with the *de novo* sequences. The database search used Comet (version 2018.01 rev. 1) (14), followed by PeptideProphet (15) using the Trans-Proteomic Pipeline (v5.0.0 Typhoon) (16). Novor was used to determine *de novo* sequences for spectra that in a database search gave peptide spectrum matches (PSMs) with false discovery rates (FDR) and Comet E-values less than 0.001. If the *de novo* sequence could account for at least 70% of the high confidence database sequence, then it was defined as having been correctly determined. Having made this determination, precision-recall curves were derived. Based on this analysis, *de novo* sequences with scores of 60 or higher were combined into a single protein sequence that was appended to the appropriate FASTA file (described next).

Sequence Databases—For the analysis of a human cell line tryptic digest, Uniprot reference proteome FASTA files were used from a number of mostly chordate species - *B. floridae* (2/27/18; 28,542), *C. brachyrrhynchus* (2/27/18; 13,621), *F. catus* (3/13/18; 20,447), *G. aculeatus* (3/13/18; 20,666), *G. gorilla* (5/26/18; 21,795), *H. sapiens* (6/27/18; 21,053), *O. anatinus* (3/13/18; 21,677), *O. garnettii* (3/13/18; 19,451), *P. abelii* (5/26/18; 21,999), *P. troglodytes* (6/23/18; 23,008), *S. harrisii* (3/13/18; 18,781), *T. asiatica* (3/13/18; 10,315), and *X. laevis* (2/27/18; 41,562). For the analysis of a *C. elegans* tryptic digest, Uniprot reference proteome FASTA files were used from a few nematode species - *C. briggsae* (2/27/18; 21,725), *C. elegans* (6/27/18; 19,998), *D. viviparus* (2/26/18; 14,161), *H. bacteriophora* (3/13/18; 20,833), *N. americanus* (2/27/18; 19,125), and *O. dentatum* (2/26/18;

¹ The abbreviations used are: MS/MS, tandem mass spectrometry; CID, collision induced dissociation; ABC, ammonium bicarbonate; DDA, data dependent acquisition; PSM, peptide-spectrum match; FDR, false discovery rate; TP, true positive; FP, false positive; FN, false negative; TIC, total ion current; DIA, data independent acquisition.

25,133). The date in parentheses denotes the last time each was modified, followed by the number of protein entries. In addition, shuffled FASTA files were created from *H. sapiens* and *C. elegans* by maintaining the tryptic cleavage sites and scrambling the intervening amino acid sequences. Seawater data and FASTA files were downloaded from the Noble lab (17). The env_nr, metagenome, and meta-peptide FASTA files contained 7,003,678, 459,004, and 15,911,893 entries, respectively. Cave bear (*U. deningeri*) bone data was searched against a Uniprot reference proteome FASTA file from *A. melanoleuca* (3/13/18; 19,344) and a NCBI FASTA file from *Ursus arctos horribilis* (11/15/18; 35,412). Spotted ratfish (*H. colliei*) data was searched against a Uniprot proteome from *C. milii* (9/25/18; 19,344), and little skate (*L. erinacea*) data was also searched against *C. milii*, as well as a combination of sequence data for all chondrichthyes found in Uniprot and RefSeq (111,444 entries). Data from whole Asian psyllids (*D. citri*), was searched against two fasta files derived from Gnomon gene predictions of the *D. citri* genome (version 1.1) (20150806Diaphorina_citri_GeneModel_MCOTprotein.ahrd.fasta and NCBI_Gnomon_MCOT_AHRD_and_endosymbionts.fasta), where the latter also contains sequences of known endosymbionts (*Candidatus Carsonella ruddii*, *Candidatus Proffella armaturae*, and *Wolbachia*). These had 30,562 and 47,160 entries, respectively. DNA extracted from glacial sediments was used to make metagenome FASTA files; further details are in the supplemental section. Appended to each of these FASTA files was a list of common contaminants (<https://www.thegpm.org/crap/index.html>).

Database Searches—All database searches were performed with Comet using FASTA files that had been modified by appending high scoring *de novo* sequences. In all cases, enzymatic cleavage was semi-tryptic, allowing for up to 2 missed cleavages per peptide. This could result in matches to a partial *de novo* sequence or to combinations of multiple *de novo* sequences; however, if such matches scored higher than any FASTA-derived sequence, the latter could still be poor matches. The precursor tolerance was set to 20 ppm, and the fragment tolerance in Comet was set via a fragment bin tolerance value of 0.02 *m/z* units. Either iodoacetamide or methyl methanethiosulfonate were used, as appropriate (only the psyllid proteome was modified using the latter), for static modifications of cysteine. Variable modifications included oxidized methionine, acetylation of the protein N terminus, and cleavage of the protein N-terminal methionine. The concatenated decoy search option was used.

The resulting pep.xml file output from Comet was then modified using a custom Python script to deal with the observation that correct sequences derived from a FASTA file entry can sometimes have a slightly lower Comet cross-correlation score than a *de novo* sequence. This occurs when the two sequences are nearly identical, but a slight sequence variation allows the *de novo* sequence to account for one or two additional minor fragment ions. Hence, in these cases the first and second rankings need to be reversed. The differences between the first and second ranked decoy sequences were used to model this effect. The rationale for this approach is that we assume all decoy sequences are incorrect regardless of their rankings, and that the first ranked decoy has a slightly higher score because of some extra random matches. This is like when a *de novo* sequence score is slightly higher than a correct FASTA file sequence score. To account for the effect of peptide size on cross-correlation scores, these decoy differences were normalized to the peptide molecular weight. The suitability of this modeling is demonstrated in [supplemental Fig. S1](#), which shows the close match between score differences. The algorithm sorts the decoy score difference (normalized by MW), and counts down through a specified percent of the list (1% is used in all cases described here) to extract a normalized score difference that can be used as a cutoff. Score differences less than that cutoff would capture 99% of the decoy score differences. Likewise, these

score differences would capture about 99% of the cases when a *de novo* sequence scores slightly better than a target FASTA sequence.

Once the Comet pep.xml file has been modified thus, PeptideProphet (15) was used to determine the FDR where the cutoff was 0.01 in conjunction with the Comet E-value cutoff of 0.01 (the only exception being the determination of high confidence sequences for Novor score evaluations as described above).

Python 2.7 scripts were written to produce precision-recall tables for evaluating Novor results, extracting high scoring sequences produced by Novor and appending them to a FASTA file, and to manipulate Comet pep.xml files before analysis by PeptideProphet, and are available at bitbucket.org/rj8/fasta_quality.

RESULTS

Evaluation of the Novor Sequence Score—The automatic *de novo* sequencing program Novor produces an overall sequence score for each sequence that ranges between 0 and 100, where the higher number indicates a better match. To understand how to interpret this score, human tryptic peptides were analyzed in four ways with combinations of beam CID *versus* resonance CID and high *versus* low mass accuracy MS/MS measurements on a Thermo Fusion orbitrap mass spectrometer using DDA. For each analysis, peptides were identified using a database search (Comet followed by PeptideProphet) of a human FASTA file. The FDR and Comet E-value limits were both set at 0.001. These PSMs were assumed to be correct and were compared with the Novor-derived sequences from the same MS/MS spectra. This sounds simple enough, however, matching *de novo* and database sequences is not straightforward.

De novo sequences are usually not completely correct but are often partially correct. One obvious error would be because of the inability to differentiate isomeric amino acids (leucine and isoleucine). Sometimes a handful of low intensity or absent sequencing ions results in short regions of poorly defined sequence in an otherwise correct sequence. A good automated *de novo* sequencing program should be able to handle short regions of poorly defined sequence and still provide a partially correct sequence with a high score. In contrast, bad spectra containing insufficient fragment ions to delineate most of the sequence should receive a low score. Likewise, non-peptide tandem mass spectra (e.g. from detergent ions) generally do not result in high scoring *de novo* sequences. This tendency to produce partially correct *de novo* sequences is what makes it a challenge to compare them to database sequences, because a direct string-to-string comparison will be far too conservative. Fig. 1A illustrates a better way to make these comparisons using mass alignments (18, 19). In this mock example, the two N-terminal amino acids are reversed, which is a common mistake because of the frequent lack of sequence-defining fragment ions between the first and second amino acids. Likewise, the absence of cleavage between Ala and Gly could be construed as being because of the presence of Gln. Another example is when an adventitious fragment ion results in Gly-Gly in the *de novo* sequence when it is just Asn. To further illustrate the idea




FIG. 1. **Mass-based alignment.** A, The alignment in this panel is for illustrative purposes and shows some common *de novo* sequencing errors. One error is the inability to delineate the two N-terminal amino acids, and in this example they are reversed. Absence of a sequencing fragment ion between the third and fourth residues (A and G) could be construed as Q in that sequence position (A and G have the same mass as Q). The reverse problem might occur in the presence of an extra ion (e.g. from a co-isolated peptide), and is illustrated by GG in the *de novo* sequence, when the database sequence at that position is actually N. Leucine and isoleucine usually cannot be differentiated based on mass. Finally, the combined mass of D plus L is the same as V plus E. In this mock example, the *de novo* sequence is quite different from the database sequence; however, a mass-based alignment suggests 100% identity. In addition to this mock alignment, real examples are shown (B–D) where the top *de novo* sequence was manually aligned with the top database sequence. These illustrate cases where 75%, 50%, and 9% of the amino acid masses are aligned, respectively. Labeled spectra for these alignments are shown in [supplemental Fig. S2](#).

of mass-based alignment, Figs. 1B–D show a few actual cases where the top *de novo* sequences (all with scores > 60) were manually aligned with the top database hit (MS/MS spectra are shown in [supplemental Fig. S2](#)). In Fig. 1B there was very little fragmentation in the middle of the peptide, yet 75% of the amino acid masses could be aligned at the two termini. Likewise, 50% of the amino acid masses could be aligned at the termini in Fig. 1C; however, in this case, the *de novo* sequence mistakenly jumps between y- and b-ion series. The database sequence contains a subsequence of LLEVE, whereas the *de novo* sequence has this reversed. There is really no alignment in Fig. 1D, but this was a case where two peptides were co-fragmented—the database search picked out one of the peptides and Novor sequenced the other one. In fact, a BLAST search of the *de novo* sequence showed an exact match to a human calmodulin tryptic peptide, where Novor assigned Ala-Ala instead of carbamylated-Val at the N terminus. However, for the purposes described here, if a mass-based alignment shows that at least 70% of the peptide mass is correct, then the *de novo* sequence is considered “correct.”

Novor results were compared with database search results with very low false discovery rates (<0.001), which were all considered to be correct. Data was collected from a tryptic digest of a human K562 cell lysate on a Thermo Fusion Orbitrap mass spectrometer that employed either resonance CID (occurring in the linear ion trap) or beam CID (so-called HCD), and either high or low accuracy/resolution measurements (orbitrap or linear ion trap, respectively). True positives (TP) are the number of correct *de novo* sequences at or above a given Novor sequence score. False positives (FP) are the number of incorrect *de novo* sequences at or above a given score. False negatives (FN) are the number of correct *de novo* sequences below a given score. It should be noted again that a “correct” *de novo* sequence only needs to be able to mass align 70% of the peptide molecular weight (Fig. 1A). Fig. 2A

shows the number of *de novo* sequences whose sequence score exceeds the score necessary to result in a specified precision, and Fig. 2B shows the precision—recall curves for the same data.

$$\text{Precision} = \text{TP}/(\text{TP} + \text{FP})$$

$$\text{Recall} = \text{TP}/(\text{TP} + \text{FN})$$

Novor is most successful if fragment ion masses are measured with high accuracy and resolution. The effect of activation type (resonance *versus* beam CID) depended on the mass accuracy—beam CID is better for high accuracy fragment mass measurement, and resonance CID is better for low accuracy. This most likely reflects the types of data used to train Novor, and not anything intrinsic to the information content of beam *versus* resonance CID fragmentations. [Supplemental Table S1](#) shows the Novor scores and number of *de novo* sequences obtained for beam and resonance CID with accurate mass MS/MS data for a few different precision values. For example, if a precision of 0.95 is acceptable, a Novor sequence score threshold of 58 was able to recall over 91% of the correct *de novo* sequences when using beam CID. In this case, there were 12,342 *de novo* sequences out of a total of 16,062 spectra identified in a database search, of which 5% were incorrect (as defined above). Hence, a Novor sequence score threshold in the range of 60 to 70 would seem to be an appropriate choice for selecting *de novo* sequences for further consideration. Similarly, [supplemental Table S2](#) shows results for linear trap MS/MS data. All subsequent data was acquired using beam CID with high mass accuracy orbitrap mass measurements of the fragment ions.

Initial Assessment of LC-MS/MS Data Using De Novo Sequencing—It can be difficult to evaluate and troubleshoot a new sample preparation method or a new type of sample, especially when there is no obvious FASTA file to search. One typically examines the general appearance of the total ion




FIG. 2. **Effect of mass accuracy and dissociation type on *de novo* sequencing using Novor.** Using a human cell line tryptic digest, data was acquired on a Lumos hybrid mass spectrometer using quadrupole isolation with beam CID and orbitrap MS2, resonance CID and orbitrap MS2, resonance CID and linear ion trap MS2, or beam CID and linear ion trap MS2. Data was searched against a human FASTA file, using an FDR cutoff of 0.001 and a Comet E-value cutoff of 0.001, PSMs were assumed correct, and compared with Novor results. Panel (A) shows the number of *de novo* sequences versus precision, and panel (B) shows the precision-recall curve for the same data.

current (TIC) plot, evaluates the precursor charge states, and counts the number of tandem mass spectra triggered using DDA. Given the speed of Novor, it makes sense to also evaluate the numbers of *de novo* sequences before database searches, where you can learn what fraction of the MS/MS spectra are high quality peptide spectra, the precursor charge states of these spectra, and the number of unique *de novo* sequences that have been derived. To simulate lower quality MS/MS spectra, varying numbers of fragment ions in a LC-MS/MS file from a human tryptic digest analyzed using a Q-Exactive HF were randomized. The randomization occurred in such a manner as to maintain the appropriate mass defect by randomly adding or subtracting an integer (1 to 9) (supplemental Table S3). Even when only 5% of the fragment ions were randomized, there was a significant decrease in the number of high scoring *de novo* sequences. Supplemental Table S4 shows a less contrived example of different tryptic digests of Greenland glacier melt water that had been concentrated and subjected to tryptic digestion followed by LC-MS/MS. These results demonstrate the presence of thousands of high-quality peptide MS/MS spectra derived from samples that were very difficult to process and not particularly rich in protein content. At this point, one could conclude that there are many peptide MS/MS spectra present in the data, although it remains to be established how many are because of human contaminant proteins.

Method For Using Automated De Novo Sequencing to Evaluate Sequence Database Suitability—Fig. 3 shows an outline of the approach, which seeks to compare the fraction of MS/MS spectra that can be confidently matched to peptide sequences in the database to the fraction that are instead better interpreted by *de novo* sequencing. High scoring *de novo* sequences are appended into a single large bogus pro-

tein with a unique header line, e.g. “>nv 000000 NOVOR_NOVOR.” This mock protein sequence is appended to the end of the FASTA file to be tested. Next, the modified FASTA file is searched using a standard database search program, such as Comet, followed by FDR determinations using PeptideProphet. Hence, the Comet scoring scheme and FDR calculations are applied to both FASTA database sequences and any competing *de novo* sequences. For a given FDR, one then counts the number of *de novo* and database sequences to calculate the database quality.

Database quality = # database sequences/

(# database sequences + # *de novo* sequences)

To determine this database quality, one needs to be able to handle the incomplete sequence information present in a typical MS/MS spectrum, and to recognize when a database derived sequence and a *de novo* result are essentially tied (e.g. supplemental Table S5), with the tie going to the database. When is the database sequence score close enough to the *de novo* score to be considered a tie? To make this determination, we hypothesize that the top two decoy matches are similarly “close enough.” For all spectra that contain at least two decoys within the top 10 sequence matches, cross-correlation score differences are calculated. Because cross-correlation scores increase with the size of the peptide, these differences were normalized to molecular weight and sorted from high to low (i.e. from large differences between the two decoy scores to zero difference). To capture 100% of the instances where a correct FASTA-derived sequence is ranked second after a *de novo* sequence, one could use the greatest decoy difference as the cutoff. A more conservative approach would capture just a fraction of the total




FIG. 3. **De novo analysis of FASTA file quality.** Using Novor, *de novo* sequences are derived for all tandem mass spectra. *De novo* sequences of suitably high quality are appended to create a novel large protein, which is then itself appended to the FASTA file under study. A database search using Comet creates a pep.xml file output. Instances where a *de novo* sequence ranks slightly higher than a FASTA-derived sequence are re-ranked to put the FASTA peptide on top. PeptideProphet then establishes the FDR. The fraction of unique peptides matching the original FASTA file out of all unique sequences, including *de novo* sequences, represents the database quality metric.

(e.g. 99%), where the cutoff score difference would be obtained further down the sorted list (e.g. 1% of the way down). A Python script was written that derives a score difference cutoff based on decoys, and then re-ranks FASTA-derived sequences that are within this cutoff if they are ranked second to a *de novo* sequence.

To test this model, high confidence PSMs from a tryptic digest of a human cell line (using FDR and Comet E-value cutoffs of 0.001) were subjected to a repeat search of the human FASTA file to which was appended the corresponding *de novo* sequences for those high confidence PSMs. Given the stringency of the search, it is assumed in this instance that all FASTA-derived sequences are correctly determined, and that whenever a *de novo* sequence has a higher score than this is because of random, adventitious, and slightly better matches with predicted fragment ions. The score difference (*de novo* - FASTA) is normalized to the peptide molecular weight, sorted, and plotted. From the same pep.xml file, score differences between the top two decoy hits (not necessarily top overall matches) are similarly calculated and plotted. As shown in supplemental Fig. S1, these plots are very close. Similar results were obtained using a different data set obtained from a tryptic digest of *C. elegans*.

The penultimate step shown in Fig. 3 employs PeptideProphet to determine error rates and probabilities using this modified pep.xml file. The number of *de novo* sequences that were clearly better than any alternative database sequence (again, using the cutoff derived from the top two decoys) can

be ascertained by filtering for “NOVOR_NOVOR” as part of the header line of the bogus *de novo* protein. In this manner, the number of unique *de novo* sequences can be compared with the total (unique FASTA and *de novo* sequences combined), and the database quality metric is calculated as the final step. When the number of unique *de novo* sequences is low, then the database quality is high. When the number of unique *de novo* sequences is high, then the database quality is low. Next, we apply this method to several practical situations to evaluate what percentages might be considered high or low values.

Evaluating FASTA Files from Similar Species—Situations can arise where proteomic data are acquired for a species that lacks a complete protein sequence database (or genome). In these cases, one would search against a FASTA file from a closely related species. The question naturally arises as to whether the chosen database is close enough. The pipeline in Fig. 3 was tested by comparing searches from a variety of related and unrelated organisms. The data in Fig. 4 and supplemental Table S6 show what happens when human proteomic data is searched against various FASTA file protein sequence databases. Searching against a human database produced 19,693 unique sequences, of which 90.8% matched best to a human FASTA sequence. The remainder could be because of sequence variants and unexpected modifications. When the human database was shuffled before appending the *de novo* sequences, 0.4% of the unique sequences matched




FIG. 4. Searching LC-MS/MS data from human tryptic peptides against various FASTA files. *De novo* sequences were appended to FASTA files from various chordates, a tape worm, and a human FASTA file that had been shuffled (keeping the original tryptic cleavage sites but shuffling intervening sequences). Using a PeptideProphet FDR of 0.01 and maximum Comet E-value of 0.01, the fraction of unique peptides that best matched to FASTA file sequences are shown.

to the shuffled FASTA sequences. Repeating this analysis for closely related primates (chimp, gorilla, and orangutan) resulted in about 83–88% of the unique sequences matching to FASTA sequences, but this went down to 66.5% for the more distantly related primate *O. garnettii*. Moving away from primates, 67.9% of the unique sequences could match to house cats, and the percentages for more distantly related mammals, Tasmanian devils and platypus, went even lower to 40.1% and 49.2%, respectively. These percentages continue to drop as FASTA files from more distantly related vertebrates were searched, although all are well above the value obtained from shuffled human sequences. Even the chordate *B. floridae* had a respectable 8.8%, and not until human proteomic data was searched against tapeworms does the percentage approach that of a shuffled human FASTA file. [Supplemental Fig. S3](#) and [supplemental Table S7](#) show the results obtained when tryptic proteomic data from *C. elegans* is searched against FASTA files from other members of the nematode phylum. In this case, searches against an unshuffled and shuffled *C. elegans* FASTA file with *de novo* sequences appended resulted in 88.7% and 0.2%, respectively, of the unique sequences matching to the corresponding FASTA file. A comparison of Figs. 4 and [supplemental Fig. S3](#) show that taxonomic categorization is not a reliable guide to choosing a suitably related FASTA file. The most closely related nematode, *C. briggsae*, is in the same genus yet only about half of the unique sequences could be assigned to this worm's FASTA file. The genome sequence variations between these two taxonomically related worms (which diverged 60 million years ago) is comparable to people *versus* cats (which diverged 90 million years ago). Although choosing FASTA files from the most taxonomically related organism is the best strategy in these situations, results may vary depending on the extent of sequence divergence.

Three applications of this technique are demonstrated using proteomic data obtained from bone fragments from the extinct cave bear (*U. deningeri*), a gel extracted from a spotted ratfish (*H. colliei*), and a gel extracted from a little skate (*L. erinacea*). Until recently, the giant panda (*A. melanoleuca*) was the species most related to cave bear for which a complete proteome was available. In this case, the search was performed with hydroxyl-proline and hydroxyl-lysine as variable modifications in addition to oxidized methionine, as collagen was expected to be a major protein component in the bone. When a Comet database search was performed on the panda FASTA file to which was appended the *Novor de novo* peptide sequences, 44.7% of the unique sequences matched to the FASTA sequences (Table I). Given that these bones had been sitting in a cave for many thousands of years, we hypothesized that most or all the amide side chains had hydrolyzed. The search was repeated, except that conversion of Gln to Glu and Asn to Asp were set as static modifications. Deamidation was set as a static, rather than variable, modification to avoid unnecessarily expanding the search space, given the likelihood of complete deamidation after thousands of years in a cave. The number of unique sequences attributable to the FASTA file jumped from 44.7% to 70.2%, suggesting that most of the side chain amides had indeed hydrolyzed over time. The total number of unique sequences dropped from 1518 to 1221, which is because of the inability to match to contaminant proteins when side chain deamidation is a static modification. One might also expect that most of the methionines would be oxidized, and indeed 66 out of 89 unique sequences containing methionine were identified in the oxidized form. Recently, the proteome for brown bears (*Ursus arctos horribilis*) became available, and using side chain deamidation as a static modification, the percentage of FASTA file derived unique sequences went up to 75.4%. This

TABLE I

De novo analysis of various FASTA protein sequence databases. Analysis of LC-MS-MS data from cave bear bones (*U. deningeri*), ratfish (*H. collieri*) gel, little skate (*L. erinacea*) gel, and whole psyllids (*D. citri*). The columns labeled “Novor PSMs” and “Novor unique sequences” list the number of PSMs and unique sequences that matched best to *de novo* sequences, rather than the FASTA file sequences

Sample	FASTA file	Total PSMs	Total unique sequences	Novor PSMs	Novor unique sequences	Database PSMs (%)	Database unique sequences (%)
Cave bear bones (<i>U. deningeri</i>)	Giant Panda (<i>A. melanoleuca</i>)	4166	1518	2207	840	47.0	44.7
Cave bear bones	Giant Panda; deamidation of Asn/Gln as fixed modifications	3833	1221	1100	364	71.3	70.2
Cave bear bones	Brown bear (<i>Ursus arctos horribilis</i>); deamidation of Asn/Gln as fixed modification	3944	1245	866	306	78.0	75.4
Spotted ratfish gel (<i>H. collieri</i>)	Ghost shark (<i>C. milii</i>)	3839	2730	874	619	22.8	22.7
Little skate gel (<i>L. erinacea</i>)	Ghost shark (<i>C. milii</i>)	32,930	14,624	28,788	12,551	12.6	14.2
Little skate gel (<i>L. erinacea</i>)	All chondrichthyes	30,143	13,300	24,574	10,538	18.5	20.8
Psyllid (<i>D. citri</i>)	Psyllid (<i>D. citri</i>)	13,358	8,779	5,768	3,835	56.8	56.3
Psyllid	Psyllid plus endosymbionts	13,037	8,588	5,352	3,544	58.9	58.7

high percentage may be because various collagens are highly conserved and are major protein components of bone.

For the spotted ratfish from the northern Pacific, the nearest relative for which a complete proteome FASTA file is available is from the Australian ghost shark (*C. milii*). In this analysis, 22.7% of the unique sequences were FASTA sequences (Table I). A similar experiment was performed on a different fish, little skate (*L. erinacea*). In this case, two FASTA files were tested - the ghost shark FASTA and a file comprised of all known sequences from chondrichthyes (jawed cartilaginous) fish. The number of unique sequences attributable to the two FASTA files were 14.2% and 20.8%, respectively. The fish data suggests that the available FASTA files are not suitable for standard database searching.


Evaluating FASTA Files for Metaproteomics—Metaproteomics involves the analysis of complex samples derived from a community of unknown species. Hence, creating and evaluating a suitable protein sequence database to search is particularly challenging (2). This typically involves assembling what are often very large non-redundant databases comprised only of proteins from possible or likely species (e.g. giant panda proteins are not likely to be in filtered seawater). Alternatively, one can perform shotgun DNA sequencing, assemble the reads into a metagenome, and translate the metagenome sequences to a metaproteome (4). The assembly of a metagenome from DNA sequence reads and subsequent translation to metaproteome can introduce errors, so May *et al.* (17) have introduced the concept of a metapeptide database. In this third approach, any predicted tryptic peptide of a suitable size from a simple six-frame translation of the short DNA reads become entries in the metapeptide database. May *et al.* compared the number of identifications made from two different seawater microbiomes (Bering Strait and the Chukchi Sea). In this study, search results from the analysis of three FASTA files were compared - a pre-existing environmental non-redundant database from NCBI (*i.e.* env_nr), protein sequences translated from metagenome assemblies made from DNA sequencing of each seawater sample, and the metapep-

tide databases derived from the same DNA sequencing data. The NCBI env_nr database is an assembly of translated nucleotide sequences obtained from large environmental sequencing projects, only some of which were marine. These FASTA files and LC-MS/MS raw files were analyzed using *de novo* sequence analysis (Fig. 5), which showed that the metapeptide database is, in fact, superior for both the Chukchi Sea and Bering Strait samples. The metagenome databases appeared to be comparable to the non-redundant NCBI database. These findings, where the metapeptide FASTA file is clearly superior to either the NCBI environmental database or the assembled metagenome, mirrors the claims made by May *et al.* (17).

Studies on whole organisms provides another metaproteomics example. Asian citrus psyllids (*D. citri*) are insect vectors responsible for transmission of a bacterial pathogen responsible for citrus greening disease. In addition to the pathogen, psyllids also contain bacterial endosymbionts. Hence, the analysis of proteins in whole psyllid tryptic digests is a metaproteomics experiment that requires a FASTA file containing protein sequences from multiple organisms. Such a file was assembled from various sources and included insect, and pathogen sequences. Analysis of this FASTA file (Table I) showed that about 56.3% of the unique sequences could be matched to this combined FASTA file. This FASTA file was expanded to include endosymbiotic bacteria, but there was only a modest increase in the percentage of unique sequences attributable to the new FASTA file (58.7%). These FASTA files may still be missing some sequences, which is likely because the annotation of the Asian citrus psyllid genome is incomplete (20). However, the current database is adequate for metaproteomics experiments (9, 21–23).

A more challenging metaproteomics project currently under study is the analysis of Greenland glacier meltwater microbiomes. Samples were taken early, mid, and late in the melting season (*i.e.* summer), and melt waters coming off the glacier surface or subsurface (*i.e.* ice-rock interface) were collected, filtered, digested with trypsin, and analyzed by

FIG. 5. Comparison of FASTA files used to search sea water metaproteomics samples. Using the FASTA files and raw data from May *et al.* (17), the *de novo* approach was used to assess FASTA file quality. Shown are the percentages of peptide-spectrum matches (PSMs) for proteomic data obtained from the Bering Strait (blue) and the Chukchi Sea (orange). For each location, the error bars represent 3-fold standard deviation from three technical replicates when searching against location-specific metapeptide and metagenome FASTA files, plus a non-redundant environmental sequence database from NCBI (*env_nr*).



LC-MS/MS. The same samples were subjected to DNA sequencing to derive sample-specific metagenome databases for the purpose of generating protein sequence databases for mass spectrometric analysis. Table II shows the results of *de novo* analysis of these various FASTA files using the corresponding LC-MS/MS data. In all cases, most tandem mass spectra best matched *de novo* sequences, rather than proteins from translated metagenomes. Given that these samples contain so little protein, it seemed plausible that many of the tryptic peptides would be from contaminant proteins. However, these FASTA files had common contaminant sequences appended, yet the percentages associated with the FASTA file were still low.

DISCUSSION

Although a commercial software package (PEAKS, Bioinformatics Solutions, Inc.) can perform rapid automated *de novo* sequencing, Novor is available as freeware and more easily incorporated within academic software pipelines. Moreover, Novor is fast and accurate, and provides *de novo* sequencing results at virtually no cost. Not surprisingly, performance is considerably better with data obtained using accurate fragment mass measurements, regardless of whether ion activation employed beam CID or resonance CID. For low mass accuracy MS/MS data, Novor seem to perform better using resonance CID. This may be because of the higher information content resulting from the frequent presence of both b- and y-type fragment ions (beam CID typically has lower intensity b-type fragments at higher mass). More likely, however, is that the low accuracy data that Novor used for model training used resonance CID rather than beam CID. Further, the model available in Novor is based on tryptic peptides, so presumably *de novo* sequencing of peptides derived from other proteases would give worse results. In our hands, Novor worked well on tryptic peptides where the fragment ions are measured using high accuracy analyzers, and for low accuracy analyzers using resonance CID.

For most proteome samples, evaluation of the data quality typically involves observing that the TIC trace is reasonably abundant and that many MS/MS spectra were acquired for multiply-charged precursors. It is more difficult to make an accurate initial assessment of LCMS data from unusual samples like glacial silt, where the TIC trace may not be very intense and one is not at all certain that the precursor ions are derived from peptides. A better metric for an initial evaluation of LCMS data would be an assessment of the number of MS/MS spectra for which a high scoring *de novo* sequence can be derived. The next step would be to verify that these peptide spectra are not simply because of keratin and trypsin autolysis, which is usually accomplished by performing a database search against a FASTA file to which has been appended sequences of common contaminant proteins. A list of common contaminant proteins is readily available, but the choice and suitability of the FASTA file to which they are appended may not be obvious.

Here we demonstrate how to use *de novo* sequencing results to evaluate the suitability of a chosen FASTA file - append *de novo* sequences to a FASTA file, perform a database search on this modified file, and then see what portion of the results match to the FASTA sequences compared with the *de novo* sequences. At best, spectra will match to the FASTA-derived sequences about 90% of the time but can match almost none when such FASTA sequences have been scrambled. When a species under study lacks a good FASTA file, one would typically attempt to use a taxonomically related species. For example, human peptides matched to other hominidae family members over 80% of the time, but *C. elegans* matched to *C. briggsae* about half the time. Hence, taxonomic relatedness does not guarantee success, and a metric for determining the suitability of a FASTA file is needed.

Although this technique provides a metric, it does not provide information on how to resolve a problem. Matching a low

TABLE II

De novo analysis of FASTA files created from metagenomes obtained from various melt water sources from a Greenland glacier. Five melt water samples obtained from early, mid, and late summer collected from either the glacier surface or subsurface (rock-ice interface)

Melt water	Total PSMs	Total unique sequences	Novor PSMs	Novor unique sequences	Database PSMs (%)	Database unique sequences (%)
Surface melt; early season	3325	1736	2371	1399	28.7	19.4
Subsurface melt; early season	3411	1623	1810	1025	46.9	36.8
Subsurface melt; mid season	4691	2077	2620	1483	44.1	28.6
Surface melt; mid season	4438	2116	2637	1456	40.6	31.2
Subsurface melt; late season	3523	1407	2369	1188	32.8	15.6

percentage of peptide MS/MS spectra to a given FASTA file can occur for a couple of reasons - the presence of modified peptides or the absence of the correct sequences in the FASTA file. Cave bear bone data did not match well to the giant panda database until the database search was performed with statically modified (*i.e.* deamidated) glutamine and asparagine. This illustrates one reason for having a poor match - the data itself may be from heavily modified or randomly cleaved (non-tryptic) proteolysis. For example, if the peptides were heavily carbamylated by urea, these would likely produce high scoring *de novo* sequences that contain sufficient sequence errors to accommodate the mass addition because of carbamylation but would not match to a FASTA-derived sequence. In the case of a proteome sample that had been lying about in a cave for thousands of years, a reasonable hypothesis that the amide side chains had been hydrolyzed could be tested. However, assuming good sample preparation technique, the most likely explanation for low FASTA matches is that the FASTA file is missing the correct sequences. The method described here provides a way to evaluate various FASTA files. For the seawater data where there were three FASTA files to evaluate—env_nr, metagenome, and metapeptide—it was found that the latter was the better choice. Likewise, the brown bear FASTA file was better than the giant panda FASTA file for analyzing the cave bear data, and the FASTA file containing all known jawed cartilaginous fish sequences was better than the FASTA file that only contained ghost shark sequences for analyzing little skate samples. In contrast, the additional sequences added to the FASTA file for analyzing the psyllid data made only a modest improvement, underscoring the importance of high-quality genome annotations for the development of proteomic databases.

Not addressed here is the question of what to do with the cases where the *de novo* sequences are clearly better than any FASTA-derived sequence. As just described, these are due either to novel sequences or modified peptides (including unexpected proteolysis). One option is to perform homology-based searches (*e.g.* BLAST) using the *de novo* sequences; however, given that *de novo* sequences are usually not completely correct (Fig. 1), such homology searches ideally would be modified to take these sequencing errors into account. CIDentify (18) and OpenSea (19) were two of the early at-

tempts, where the general approach is to match short stretches of *de novo* sequences before performing mass-based alignments in the surrounding region of sequences. However, these two computer programs are either unavailable or too slow given the volume of data nowadays. PEAKS provides a commercial solution, but this requires a monetary outlay that might be prohibitive. This topic is worth revisiting, given the availability and capabilities of Novor. A second option might employ an open modification search strategy to try to identify these novel sequences or modified peptides (24), and a third option would be to perform a search using an extended FASTA database (25).

Finally, this approach for evaluating FASTA files can also be used on data independent acquisition (DIA) data. One would simply run Novor on the pseudo-MS/MS spectra produced by the DIA-Umpire signal extraction module (26) and proceed in the same manner described here (27).

Acknowledgments—We thank Bin Ma for his assistance in using Novor. We also thank Richard E. Green for providing the cave bear bone sample.

DATA AVAILABILITY

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (28) via the PRIDE (29) partner repository with the dataset identifier PXD015083 and 10.6019/PXD015083 (<https://www.ebi.ac.uk/pride/archive/>).

* This study was supported by P41 GM103533 and R01 GM121696 to M.J.M. The authors declare that they have no conflicts of interest with the contents of this article.

§ This article contains [supplemental material](#).

‡‡ To whom correspondence should be addressed. Tel.: 1-206-616-9023; E-mail: rj8@uw.edu.

§§ Currant address: Seattle Genetics, Bothell, Washington.

Author contributions: R.J. designed research; R.J., J.M.G., and M.P. performed research; R.J., B.C.S., B.L.N., J.M.G., M.P., C.T.A., and M.H. contributed new reagents/analytic tools; R.J. analyzed data; R.J. wrote the paper; B.C.S. edited. Designed graphical abstract. Conceived the idea of using decoys to determine ties between fasta and denovo sequences.; B.L.N. designed procedure for proteomic prep of glacial melt.; J.M.G. performed the proteomic prep of the glacial melt.; M.J.M. provided space and funding to perform this research. Also edited manuscript.

REFERENCES

- Eng, J. K., Searle, B. C., Clauser, K. R., and Tabb, D. L. (2011) A face in the crowd: recognizing peptides through database search. *Mol. Cell. Proteomics* **10**, 1–9
- Timmins-Schiffman, E., May, D. H., Mikan, M., Riffle, M., Frazar, C., Harvey, H. R., Noble, W. S., and Nunn, B. L. (2017) Critical decisions in metaproteomics: Achieving high confidence protein annotations in a sea of unknowns. *ISME J.* **11**, 309–314
- Cilia, M., Tamborindeguy, C., Rolland, M., Howe, K., Thannhauser, T. W., and Gray, S. (2011) Tangible benefits of the aphid *Acyrtosiphon pisum* genome sequencing for aphid proteomics: Enhancements in protein identification and data validation for homology-based proteomics. *J. Insect Physiol.* **57**, 179–190
- Ruggles, K. V., Krug, K., Wang, X., Clauser, K. R., Wang, J., Payne, S. H., Fenyo, D., Zhang, B., and Mani, D. R. (2017) Methods, tools and current perspectives in proteogenomics. *Mol. Cell. Proteomics* **16**, 959–981
- Ma, B., and Johnson, R. (2012) De novo sequencing and homology searching. *Mol. Cell. Proteomics* **11**, 1–16
- Ma, B. (2015) Novor: Real-time peptide de novo sequencing software. *J. Am. Soc. Mass Spectrom.* **26**, 1885–1894
- Taylor, J. A., and Johnson, R. S. (2001) Implementation and uses of automated de novo peptide sequencing by tandem mass spectrometry. *Anal. Chem.* **73**, 2594–2604
- Merrihew, G. E., Davis, C., Ewing, B., Williams, G., Käll, L., Frewen, B. E., Noble, W. S., Green, P., Thomas, J. H., and MacCoss, M. J. (2008) Use of shotgun proteomics for the identification, confirmation, and correction of *C. elegans* gene annotations. *Genome Res.* **18**, 1660–1669
- Ramsey, J. S., Johnson, R. S., Hoki, J. S., Kruse, A., Mahoney, J., Hilf, M. E., Hunter, W. B., Hall, D. G., Schroeder, F. C., MacCoss, M. J., and Cilia, M. (2015) Metabolic interplay between the asian citrus psyllid and its proffella symbiont: An achilles' heel of the citrus greening insect vector. *PLoS ONE* **10**, 1–21
- Bon, C., Caudy, N., de Dieuleveult, M., Fosse, P., Philippe, M., Maksud, F., Beraud-Colomb, E., Bouzaid, E., Kefi, R., Laugier, C., Rousseau, B., Casane, D., van der Picht, J., and Elalouf, J. M. (2008) Deciphering the complete mitochondrial genome and phylogeny of the extinct cave bear in the Paleolithic painted cave of Chauvet. *Proc. Natl. Acad. Sci.* **105**, 17447–17452
- Noonan, J. P., Hofreiter, M., Smith, D., Priest, J. R., Rohland, N., Rabeder, G., Krause, J., Dettler, J. C., Pääbo, S., and Rubin, E. M. (2005) Genomic sequencing of Pleistocene cave bears. *Science* **309**, 597–599
- Dabney, J., Knapp, M., Glocke, I., Gansauge, M.-T., Weihmann, A., Nickel, B., Valdiosera, C., Garcia, N., Paabo, S., Arsuaga, J.-L., and Meyer, M. (2013) Complete mitochondrial genome sequence of a Middle Pleistocene cave bear reconstructed from ultrashort DNA fragments. *Proc. Natl. Acad. Sci.* **110**, 15758–15763
- Chambers, M. C., Maclean, B., Burke, R., Amodei, D., Ruderman, D. L., Neumann, S., Gatto, L., Fischer, B., Pratt, B., Egertson, J., Hoff, K., Kessner, D., Tasman, N., Shulman, N., Frewen, B., Baker, T. a., Brusniak, M.-Y., Paulse, C., Creasy, D., Flashner, L., Kani, K., Moulding, C., Seymour, S. L., Nuwaysir, L. M., Lefebvre, B., Kuhlmann, F., Roark, J., Rainer, P., Detlev, S., Hemenway, T., Huhmer, A., Langridge, J., Connolly, B., Chadick, T., Holly, K., Eckels, J., Deutsch, E. W., Moritz, R. L., Katz, J. E., Agus, D. B., MacCoss, M. J., Tabb, D. L., and Mallick, P. (2012) A cross-platform toolkit for mass spectrometry and proteomics. *Nat. Biotechnol.* **30**, 918–920
- Eng, J. K., Jahan, T. a., and Hoopmann, M. R. (2012) Comet: an open source tandem mass spectrometry sequence database search tool. *Proteomics* **13**, 1–3
- Keller, A., Nesvizhskii, A. I., Kolker, E., and Aebersold, R. (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. *Anal. Chem.* **74**, 5383–5392
- Deutsch, E. W., Mendoza, L., Shteynberg, D., Farrah, T., Lam, H., Sun, Z., Nilsson, E., Pratt, B., Prazan, B., Eng, J. K., Daniel, B., Nesvizhskii, A. I., and Aebersold, R. (2010) A guided tour of the trans-proteomic pipeline Tasman8. *Proteomics* **10**, 1150–1159
- May, D. H., Timmins-Schiffman, E., Mikan, M. P., Harvey, H. R., Borenstein, E., Nunn, B. L., and Noble, W. S. (2016) An alignment-free “metapeptide” strategy for metaproteomic characterization of microbiome samples using shotgun metagenomic sequencing. *J. Proteome Res.* **15**, 2697–2705
- Taylor, J. A., and Johnson, R. S. (1997) Sequence database searches via de novo peptide sequencing by tandem mass spectrometry. *Rapid Commun. Mass Spectrom.* **11**, 1067–1075
- Searle, B. C., Dasari, S., Turner, M., Reddy, A. P., Choi, D., Wilmarth, P. A., McCormack, A. L., David, L. L., and Nagalla, S. R. (2004) High-throughput identification of proteins and unanticipated sequence modifications using a mass-based alignment algorithm for MS/MS de novo sequencing results. *Anal. Chem.* **76**, 2220–2230
- Saha, S., Hosmani, P. S., Villalobos-Ayala, K., Miller, S., Shippy, T., Flores, M., Rosendale, A., Cordola, C., Bell, T., Mann, H., DeAvila, G., DeAvila, D., Moore, Z., Buller, K., Ciolkevich, K., Nandyal, S., Mahoney, R., Van Voorhis, J., Dunlevy, M., Farrow, D., Hunter, D., Morgan, T., Shore, K., Guzman, V., Izsak, A., Dixon, D. E., Cridge, A., Cano, L., Cao, X., Jiang, H., Leng, N., Johnson, S., Cantarel, B. L., Richards, S., English, A., Shatters, R. G., Childers, C., Chen, M. J., Hunter, W., Cilia, M., Mueller, L. A., Munoz-Torres, M., Nelson, D., Poelchau, M. F., Benoit, J. B., Wiersma-Koch, H., D'Elia, T., and Brown, S. J. (2017) Improved annotation of the insect vector of citrus greening disease: biocuration by a diverse genomics community. *Database* **2017**, 1–20
- Ramsey, J. S., Chavez, J. D., Johnson, R., Hosseinzadeh, S., Mahoney, J. E., Mohr, J. P., Robison, F., Zhong, X., Hall, D. G., MacCoss, M. J., Bruce, J., and Cilia, M. (2017) Protein interaction networks at the host-microbe interface in *Diaphorina citri*, the insect vector of the citrus greening pathogen. *R. Soc. Open Sci.* **4**, 160545
- Kruse, A., Ramsey, J. S., Johnson, R., Hall, D. G., MacCoss, M. J., and Heck, M. (2018) *Candidatus liberibacter asiaticus* minimally alters expression of immunity and metabolism proteins in hemolymph of *Diaphorina citri*, the insect vector of Huanglongbing. *J. Proteome Res.* **17**, 2995–3011
- Kruse, A., Fattah-Hosseini, S., Saha, S., Johnson, R., Warwick, E. R., Sturgeon, K., Mueller, L., MacCoss, M. J., Shatters, R. G., and Heck, M. C. (2017) Combining omics and microscopy to visualize interactions between the Asian citrus psyllid vector and the Huanglongbing pathogen *Candidatus Liberibacter asiaticus* in the insect gut. *PLoS ONE* **12**, 1–28
- Kong, A. T., Leprevost, F. V., Avtonomov, D. M., Mellacheruvu, D., and Nesvizhskii, A. I. (2017) MSFragger: Ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics. *Nat. Methods* **14**, 513–520
- Binz, P. A., Shofstahl, J., Vizcaino, J. A., Barsnes, H., Chalkley, R. J., Menschaert, G., Alpi, E., Clauser, K., Eng, J. K., Lane, L., Seymour, S. L., Sánchez, L. F. H., Mayer, G., Eisenacher, M., Perez-Riverol, Y., Kapp, E. A., Mendoza, L., Baker, P. R., Collins, A., Van Den Bossche, T., and Deutsch, E. W. (2019) Proteomics standards initiative extended FASTA format. *J. Proteome Res.* **18**, 2686–2692
- Tsou, C.-C., Avtonomov, D., Larsen, B., Tucholska, M., Choi, H., Gingras, A.-C., and Nesvizhskii, A. I. (2015) DIA-Umpire: comprehensive computational framework for data-independent acquisition proteomics. *Nat. Methods* **12**, 258–264
- Johnson, R. S., Searle, B., Keller, A., and MacCoss, M. J. (June 4–8, 2017) De novo DIA Analysis (DDA). In *Proceedings of the 65th ASMS Conference on Mass Spectrometry and Allied Topics*, Indianapolis, Indiana
- Deutsch, E. W., Csordas, A., Sun, Z., Jarnuczak, A., Perez-Riverol, Y., Ternent, T., Campbell, D. S., Bernal-Llinares, M., Okuda, S., Kawano, S., Moritz, R. L., Carver, J. J., Wang, M., Ishihama, Y., Bandeira, N., Hermjakob, H., and Vizcaino, J. A. (2017) The ProteomeXchange consortium in 2017: Supporting the cultural change in proteomics public data deposition. *Nucleic Acids Res.* **45**, D1100–D1106
- Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D. J., Inuganti, A., Griss, J., Mayer, G., Eisenacher, M., Pérez, E., Uszkoreit, J., Pfeuffer, J., Sachsenberg, T., Yilmaz Ş Tiwary, S. Cox, J., Audain, E., Walzer, M., Jarnuczak, A. F., Ternent, T., Brazma, A., and Vizcaino, J. A. (2019) The PRIDE database and related tools and resources in 2019: Improving support for quantification data. *Nucleic Acids Res.* **47**, D442–D450